Iloperidone (Fanapt) vs Olanzapine (Zyprexa Relprevv)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIloperidone (Fanapt)Olanzapine (Zyprexa Relprevv)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
—Not posted · NCT00088491
CGI-S, change—Trial running · NCT06961968-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
PANSS response—Trial running · NCT06961968—Not posted · NCT00088491
PSP, change—Trial running · NCT06961968—Not posted · NCT00088491
Relapse (% of patients)—Trial running · NCT0696196820.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Iloperidone (Fanapt): 4 of 4 rows · Olanzapine (Zyprexa Relprevv): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Olanzapine (Zyprexa Relprevv)
Dropout rate
34.6%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
54.9%b
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
9.8%b
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Serious AEs
0.7%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
9.5%b
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
b
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

PANSS Total -12 vs -7.1 placebo score @ 4wk
absolute change · score
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 1 more result
1.1 vs 12.4 placebo score @ 26wk
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
Time to Relapse NA vs 3.25 placebo months @ 26wk
time to event · months
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Olanzapine (Zyprexa Relprevv)'s landscape